Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505)

Clinical Lung Cancer

Volumn 14, Issue 2, 2013, Pages 103-107

  Chouaid, Christos ^a   Le Caer, Hervé ^b   Corre, Romain ^c   Crequit, Jacquy ^d   Locher, Chrystelle ^e   Falchero, Lionel ^f   Dujon, Cecile ^g   Berard, Henri ^h   Monnet, Isabelle ⁱ   Vergnenegre, Alain ^j  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b CH de Draguignan   (France)

^c RENNES UNIVERSITY HOSPITAL   (France)

^d CH de Creil Beauvais   (France)

^e CH de Meaux   (France)

^f CH de Villefranche   (France)

^g CH Versailles   (France)

^h Military Teaching Hospital Sainte Anne   (France)

ⁱ CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^j LIMOGES UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Cost utility; Elderly patients; Erlotinib; Phase II trial

Indexed keywords

ERLOTINIB; ERYTHROPOIETIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER STAGING; COMORBIDITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; FRAIL ELDERLY; HISTOLOGY; HOSPITALIZATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SMOKING; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; FEMALE; FRAIL ELDERLY; HUMANS; LUNG NEOPLASMS; MALE; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; QUALITY-ADJUSTED LIFE YEARS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84875247288     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2012.04.006     Document Type: Article

References (20)

1. C. Chouaid, K. Atsou, G. Hejblum Economics of treatments for non-small cell lung cancer Pharmacoeconomics 27 2009 113 125
2. A.G. Pallis, V. Georgoulias Is there a standard regimen for first-line treatment of advanced/metastatic non-small-cell lung cancer? What has meta-analyses contributed to today's standard of care Lung Cancer 75 2012 269 274
3. A. Jatoi, S. Hillman, P. Stella Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group J Clin Oncol 23 2005 9113 9119
4. C. Gridelli, P. Maione, A. Illiano Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies J Clin Oncol 25 2007 4663 4669
5. C. Gridelli, E. Kaukel, V. Gregorc Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial J Thorac Oncol 2 2007 221 229
6. P. Comella, G. Frasci, P. Carnicelli Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients Br J Cancer 91 2004 489 497
7. G. Frasci, V. Lorusso, N. Panza Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer A Southern Italy Cooperative Oncology Group (SICOG) phase III trial Lung Cancer 34 suppl 4 2001 S65 S69
8. C. Gridelli, F. Perrone, C. Gallo Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the multicenter Italian lung cancer in the elderly study (MILES) phase III randomized trial J Natl Cancer Inst 95 2003 362 372
9. S. Ricci, A. Antonuzzo, L. Galli Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study Lung Cancer 27 2000 75 80
10. P. Wheatley-Price, K. Ding, L. Seymour Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21 J Clin Oncol 26 2008 2350 2357
11. D.M. Jackman, B.Y. Yeap, N.I. Lindeman Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for non-small-cell-lung advanced cancer J Clin Oncol 25 2007 760 766
12. LeCaer H, Greillier L, Corre R, et al. GFPC 0505 Team. A multicenter phase II randomized trial of gemcitabine followed by erlotinib on progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0505 study). Lung Cancer, Published online March 7, 2012. PMID: 22405570.
13. G. Lewis, M. Peake, R. Aultman Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom J Int Med Res 38 2010 9 21
14. B. Nafees, M. Stafford, S. Gavriel Health state utilities for non small cell lung cancer. Health and Quality of Life Outcomes http://www.ncbi.nlm.nih. gov/pmc/articles/PMC2579282/pdf/1477-7525-6-84.pdf 2008 Accessed: January 20, 2012
15. Ministère de la Santé et des Solidarités. Arrêté du 27 février 2007 relatif à la classification et à la prise en charge des prestations d'hospitalisation pour les activités de médecine, chirurgie, obstétrique et odontologie et pris en application de l'article L. 162-22-6 du code de la sécurité sociale. Journal Officiel n°50 du 28 février 2007, texte 72.
16. Nomenclature Générale des Actes Professionnels Union des Caisses Nationales de Sécurité Sociale (UCANSS). Paris http://www.ameli.fr/fileadmin/user-upload/documents/NGAP-oct-2009.pdf Accessed: January 20, 2012
17. C. Chouaid, L. Molinier, C. Combescure Economics of the clinical management of lung cancer in France: an analysis using a Markov model Br J Cancer 90 2004 397 402
18. P.A. Bradbury, D. Tu, L. Seymour Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer J Natl Cancer Inst 102 2010 298 306
19. J.J. Carlson, C. Reyes, N. Oestreicher Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC) Lung Cancer 61 2008 405 415
20. C. Chouaid, H. Lecaer, J. Crequit Cost-effectiveness of erlotinib in first line treatment of non small cell lung cancer (NSCLC) in elderly patients: an economical analysis of a prospective phase 2 study (GFPC 0504) Value Health 13 2010 A267